Keyphrases
Heart Failure
86%
Heart Failure Patients
75%
Patients with Heart Failure
60%
Type 2 Diabetes Mellitus (T2DM)
53%
Heart Failure Hospitalization
48%
Type 2 Diabetic Patients
42%
Temporal Trends
41%
Confidence Interval
37%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
35%
Estimated Glomerular Filtration Rate
35%
GLP-1 Receptor Agonist
31%
Frailty
29%
New Onset
23%
Atrial Fibrillation
23%
Hazard Ratio
22%
Cardiovascular Disease
22%
Medical Therapy
21%
All-cause Mortality
21%
Inhibitor-1
20%
Chronic Heart Failure
20%
Iron Deficiency
20%
Ischemic Heart Disease
17%
Clinical Outcomes
16%
Heart Failure Therapy
15%
Frail Elderly
15%
Without Diabetes
15%
A1 Receptor
13%
Receptor Agonist
13%
Hospital Frailty Risk Score
13%
Real-life Cohort
13%
National Cohort Study
12%
Denmark
12%
Cardiovascular Outcomes
12%
Like Peptide
12%
Frailty Status
12%
Nationwide Registers
11%
End-stage Renal Disease
11%
Prognostic Implications
11%
Mortality Risk
11%
Absolute Risk
10%
Non-steroidal Anti-inflammatory Drugs (NSAIDs)
10%
Age-specific Mortality
10%
Atherothrombotic Event
10%
Acute Dialysis
10%
Incident Ischemic Heart Disease
10%
Diabetes Disease
10%
Mortality Trends
10%
Reinitiation
10%
Dialysis Initiation
10%
Cardiovascular Phenotype
10%
Medicine and Dentistry
Heart Failure
89%
Congestive Heart Failure
65%
Maturity Onset Diabetes of the Young
41%
Glomerular Filtration Rate
35%
Patient with Type 2 Diabetes
31%
Cardiovascular System
27%
Sodium Glucose Cotransporter 2 Inhibitor
23%
Atrial Fibrillation
23%
Glucagon
20%
Receptor
20%
Frailty
20%
End Stage Renal Disease
18%
Diabetes
14%
Ischemic Heart Disease
14%
Apoplexy
14%
Kidney Function
14%
Observational Study
13%
Cohort Analysis
12%
All Cause Mortality
11%
Heart Left Ventricle Ejection Fraction
11%
Combination Therapy
11%
Cardiovascular Disease
10%
Glucagon-Like Peptide-1 Agonist
10%
Empagliflozin
10%
Placebo
10%
Nonsteroid Antiinflammatory Agent
10%
Brain Natriuretic Peptide
10%
Adverse Outcome
10%
Amino Terminal Sequence
10%
Infection
10%
Iron Deficiency
10%
Albumin
10%
Creatinine
10%
Urinary System
10%
Patient with Hypertension
10%
Proportional Hazards Model
8%
Attributable Risk
6%
Cardiology
6%
Moderate Renal Impairment
6%
Severe Renal Impairment
5%
Lifespan
5%
Pharmacology, Toxicology and Pharmaceutical Science
Heart Failure
100%
Congestive Heart Failure
54%
Non Insulin Dependent Diabetes Mellitus
52%
Frailty
41%
Sodium Glucose Cotransporter 2 Inhibitor
24%
Cohort Study
21%
Combination Therapy
20%
Iron Deficiency
20%
End Stage Renal Disease
18%
All Cause Mortality
15%
Cardiovascular Disease
13%
Ischemic Heart Disease
13%
Atrial Fibrillation
12%
Chronic Kidney Failure
11%
Glucagon Like Peptide 1 Receptor Agonist
11%
Non-Steroidal Anti-Inflammatory Drug
10%
Glucagon
10%
Placebo
10%
Receptor Agonist
10%
Empagliflozin
10%
Metabolic Syndrome X
10%
Cross-Sectional Study
10%
Brain Natriuretic Peptide
10%
Adverse Outcome
10%
Infection
10%
Albumin
10%
Creatinine
10%
Cardiovascular Mortality
9%
Iron
6%
Moderate Renal Impairment
6%
Severe Renal Impairment
5%
